Toxicity Management for Anti-Tumor Activity of CARs

a technology of toxic management and car, which is applied in the field of toxic management of car antitumor activity, can solve the problems of insufficient investigation of car t cells on all blasts, more immature leukemia with a more rapid progression, and insufficient investigation of cytokine secretion and disorders associated with in vivo chimeric antigen recept t-cell expansion, so as to reduce or avoid an adverse effect
US20150202286A1Inactive Publication Date: 2015-07-23THE CHILDRENS HOSPITAL OF PHILADELPHIA +1
3 Cites 43 Cited by

Patent Information

Authority / Receiving Office
US · United States
Current Assignee / Owner
THE CHILDRENS HOSPITAL OF PHILADELPHIA
Publication Date
2015-07-23
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority to U.S. Provisional Patent Application No. 61 / 671,482, filed on Jul. 13, 2012 and U.S. Provisional Patent Application No. 61 / 782,982, filed on Mar. 14, 2013, each of which application is hereby incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION

[0002] Patients with relapsed and chemotherapy-refractory acute lymphocytic leukemia (ALL) have a poor prognosis despite the use of aggressive therapies such as allogeneic hematopoietic stem cell transplantation (Barrett et al., 1994, N Engl J Med 331:1253-8; Gokbuget et al., 2012, Blood 120:2032-41) and bi-specific CD19 antibody fragments (Bargou et al., 2008, Science 321:974-7). Chimeric antigen receptor modified T cells targeting lineage-specific antigens CD19 and CD20 have been reported to be effective in adults with CLL and B-cell lymphomas (Till et al., 2008, Blood 112:2261-71; Kochenderfer et al., 2010, Blood 116:4099-102; Brentjens et ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More